

REPORT DOCUMENTATION PAGE

Form Approved
OMB NO. 0704-0188

Public Reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comment regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188,) Washington, DC 20503.

1. AGENCY USE ONLY (Leave Blank)		2. REPORT DATE July 14, 2005		3. REPORT TYPE AND DATES COVERED Final Report 4/2/01 – 6/30/05	
4. TITLE AND SUBTITLE Using Phage Lytic Enzymes to Destroy Pathogenic and BW Bacteria				5. FUNDING NUMBERS DAAD19-01-1-0365	
6. AUTHOR(S) Vincent A. Fischetti					
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Rockefeller University 1230 York Avenue New York, NY 10021				8. PERFORMING ORGANIZATION REPORT NUMBER n/a	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U. S. Army Research Office P.O. Box 12211 Research Triangle Park, NC 27709-2211				10. SPONSORING / MONITORING AGENCY REPORT NUMBER 42450.1-LS	
11. SUPPLEMENTARY NOTES The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision, unless so designated by other documentation.					
12 a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited.				12 b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words) We have exploited the rapid, lethal and highly specific action of bacteriophage lytic enzymes to destroy pathogenic bacteria. Our results show that in vitro 10^7 bacteria can be reduced to sterility seconds after enzyme contact. We now have enzymes that are specific for <i>S. pyogenes</i> , <i>S. pneumoniae</i> , and <i>B. anthracis</i> <i>S. aureus</i> , <i>E. faecalis</i> / <i>E. faecium</i> and group B streptococci. In animal models, we pre-colonize mice with either streptococcal or pneumococcal species (orally or nasally) and remove them completely with a single dose of phage enzyme delivered to these sites. In a septicemia model with <i>S. pneumoniae</i> , bacteria are reduced by >2-logs from the blood of infected animals with a single intravenous dose of enzyme. A lytic enzyme called PlyG from the gamma-phage of <i>B. anthracis</i> was specific for all worldwide isolates of <i>B. anthracis</i> . When >1 LD ₁₀₀ of <i>B. anthracis</i> bacilli were delivered i.v. to mice only 10% of animals, followed for 12 days, survived. When PlyG was injected i.v. 15 min after infection, 90% of the mice recovered fully. Resistance to the enzymes has not been found nor do antibodies neutralize their activity. Thus, phage lytic enzymes are a new reagent to control resistant pathogenic bacteria, offering a capability previously unavailable.					
14. SUBJECT TERMS Phage lytic enzymes, Lysins, <i>B. anthracis</i> ,				15. NUMBER OF PAGES 6	
				16. PRICE CODE	
17. SECURITY CLASSIFICATION OR REPORT UNCLASSIFIED	18. SECURITY CLASSIFICATION ON THIS PAGE UNCLASSIFIED	19. SECURITY CLASSIFICATION OF ABSTRACT UNCLASSIFIED	20. LIMITATION OF ABSTRACT UL		

FINAL REPORT

Principal Investigator Name: Vincent A. Fischetti

Contract Number: DAAD19-01-1-0365

Title: Using Phage Lytic Enzymes to Destroy Pathogenic and BW Bacteria

Phone: 212-327-8166

Fax: 212-326-7584

E-mail: vaf@mail.rockefeller.edu

Web: www.rockefeller.edu/vaf

Project Goals: We have developed a novel method to kill biowarfare bacteria (particularly *B. anthracis*) safely and quickly. This method exploits the rapid yet specific activity of bacteriophage lytic enzymes to destroy these bacteria on contact. During the course of this grant we planned to develop enzymes that control *B. anthracis*. In preliminary experiments in vitro, 10 micrograms of PlyG lysin from the gamma-phage could reduce the viability of 10^7 bacilli by >6-logs in minutes. In vivo, we were able to save the lives of animals infected intravenously with the Ames strain of anthrax. Our goal was to identify a number of enzymes from a variety of phage to control *B. anthracis*.

Final Report: During the tenure of this grant we were successful in identifying several phage enzymes specific for *B. anthracis*. These enzymes were cloned from the gamma phage (PlyG) and from lysogenic phage found in the *B. anthracis* genome (PlyPH). In animal model experiments, we were able to infect mice intravenously (iv) with the Ames strain of anthrax and using a single PlyG enzyme dose, save the lives of 70%-90% of the animals whereas 100% of control animals died. Pharmacokinetic experiments revealed that the half-life of these enzymes was about 20 minutes, necessitating the delivery of the enzyme by constant iv infusion to attain maximum effects.

In the presence of a germinating solution, spores will germinate within a minute after exposure. We discovered that in the presence of germinant and lysin, the spore viability could be reduced by >3 logs within 20 minutes. During these studies, we identified a lysin (PlyPH) from a lysogen in the *B. anthracis* genome which retained its lytic activity from pH 4.0 – 8.5. This enzyme has the broadest pH activity range of all reported lysins. We believe that this characteristic and the fact that this enzyme is stable at 60C will be beneficial for its use as a decon enzyme, to remove both spores and vegetative bacilli from the environment and military vehicles.

During the course of this work, we have isolated a number of additional phage that have activity against *B. anthracis*. One of these phage stands out in that we have found that it is more specific for *B. anthracis* than the gamma-phage since it will not recognize the occasional *B. cereus* strain yielding a false positive reaction. This phage is a podoviridae, which is a rare tail-less membrane-containing phage. Because of its high specificity, we believe that this phage may replace the gamma phage as one of the diagnostic tools to identify *B. anthracis*.

We also discovered that when *B. anthracis* becomes lysogenized by its normal phage, that genes that are normally silent are expressed. These genes include, coat proteins, hemolysins, exosporium proteins, lipases and a large number of genes found in the PLCR regulon. The expression of these genes we believe will allow *B. anthracis* to survive in a vegetative state in the soil more successfully than without. This finding has opened the door to a new pathway for *B. anthracis* that was previously missed.

Publications and submitted manuscripts published during the course of this grant:

Schuch, R., D. Nelson and V.A. Fischetti. 2002. Identification of a bacteriolytic agent that can rapidly and specifically detect and kill *Bacillus anthracis*. *Nature*. 418: 884–889.

Nelson, D., Schuch, R., S. Zhu, D. Tscherne, and V.A. Fischetti. 2003. The genomic sequence of C1, the first streptococcal phage. *J. Bacteriol.* 185:3325-3332.

Loeffler, J.M, S. Djurkovic and V.A. Fischetti. 2003. The phage lytic enzyme Cpl-1 as a novel antimicrobial for pneumococcal bacteremia and sepsis. *Infect. Immun.* 71:6199-204.

Yoong, P., R. Schuch, D. C. Nelson and V. A. Fischetti. 2004. Identification of a broadly active phage lytic enzyme with lethal activity against antibiotic resistant *Enterococcus faecalis* and *Enterococcus faecium*. *J Bacteriol.* 186:4808-12.

Cheng, Q., D. Nelson, S. Zhu, and V.A. Fischetti. 2005. Removing group B streptococci colonizing the vagina and pharynx of mice with a bacteriophage lytic enzyme. *Antimicrob Agents Chemother.* 49:111-117.

Schuch, R., V.A. Fischetti. 2005. Complete genome of *B. anthracis* bacteriophages gamma and W and their role in pathogenesis. (Submitted).

Inventors**Title and RU file number**

- | | |
|--|---|
| 1. Fischetti, Vincent A,
Schuch, Raymond,
Yoong, Pauline, and Nelson, Daniel | PlyPH: a lysin active against anthrax, RU-755 |
| 2. Fischetti, Vincent A, Schuch, Raymond,
and Yoong, Pauling | Lysins from <i>Enterococcus faecalis</i> RU-654 |
| 3. Fischetti, Vincent A. Schuch, Raymond | Lytic Enzymes and spore surface antigens for
detection and treatment of <i>B. anthracis</i> bacteria and
spores, RU-651 |
| 4. Fischetti, Vincent A, Schuch, Raymond,
Nelson, Daniel | Phage-associated lytic enzymes for treatment of <i>B.</i>
<i>anthracis</i> and related conditions, RU-625 |
| 5. Fischetti, Vincent A., Loeffler, Jutta | Phage-associated lytic enzymes for treatment of
<i>Streptococcus pneumoniae</i> and related conditions,
RU-621 |
| 6. Fischetti, Vincent A, Loeffler, Jutta | Use of synergistic bacteriophage lytic enzymes for
prevention and treatment of bacterial infections,
RU-629 |